Press Releases
Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistry (IHC) 2+ or 3+ and a median OS of 18.1 months in patients with IHC 3+ tumors
With approximately two years of median follow-up, as of July 28, 2023, median duration of response (DOR) increased by two months from initial analysis to 14.9 months
DUBLIN, June 1, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced... (continue reading...)
NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new interim data from the Phase 2 Trial 201 of naxitamab in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”) in... (continue reading...)
Publication Entitled: Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial
HARMONi-A was Featured in Oral Presentation at ASCO 2024 on May 31, 2024
Conference Call to be Held at 8:00am ET on Monday, June 3, 2024
MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) announced that the Journal of the American Medical Association (JAMA) published a... (continue reading...)
BOSTON, June 1, 2024 /PRNewswire/ -- Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully replaced by alpaca IGH-VDJ genes in-situ.
In 1993, naturally occurring heavy-chain-only antibodies (HCAbs) were discovered.... (continue reading...)
KERRVILLE, Texas, June 1, 2024 /PRNewswire/ -- James Avery Artisan Jewelry, a family-owned jewelry retailer based in Texas, is excited to announce the opening of its new store at Westover Marketplace in San Antonio. The new store is located at 8219 State Highway 151, Suite 128, San Antonio, TX 78245 – next to Target.
"This year marks our 70th... (continue reading...)
More Press Releases
View Older Stories-
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
-
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
-
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
-
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
-
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
-
BALEAF & SOJOS to host "Summer it up" summer fashion extravaganza!
-
Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible patients
-
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Canc
-
Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
-
OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
-
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
-
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
-
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
-
CryptoHeap Targets Top Position in Crypto Staking Industry Before Bull Run Concludes
-
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
-
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
-
ENPH INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Enphase Energy, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Gruvtype features de Buyer Products in Global Culinary Adventure with Free "Street, Beach & Sky" Preview Cookbook
-
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemo
-
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
-
Horizon Wealth Donates $3 Million for Brazil's Post-Disaster Reconstruction
-
Eurasian Capital Participates in the Third ICPAC Mediterranean Financial Summit: Exploring the Future Frontiers of Finance
-
XAR and Salus Join Forces to Build zkLogin 'Hikari': The Final Step to Mass Adoption on Starknet
-
Brandmydispo Continues to Innovate the Custom Mylar Bag Space
-
ZEEKR Announces May 2024 Delivery Update
-
Pamela Dowell's newly released "Saucey's Adventure" is a delightful adventure of a young unicorn in an unknown land.
-
VENTYX SHAREHOLDER REMINDER: BFA Law Reminds Ventyx Biosciences, Inc. (NASDAQ: VTYX) Shareholders to Contact the Firm About Ongoing Investigation
-
SQSP (NYSE) REMINDER: BFA Law Reminds Squarespace Shareholders to Inquire About Ongoing Investigation into the $44 Buyout Offer
-
SPT (NYSE) FRAUD ALERT: Sprout Social, Inc. Investors who Lost Money when Stock Plummeted 40% are Encouraged to Contact BFA Law about Upcoming Deadline
-
PATH (NYSE) INVESTOR ALERT: UiPath, Inc. Investigated for Securities Fraud After 34% Stock Drop, Contact BFA Law if You Suffered Losses
-
CERE (NASDAQ) REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation into the $45 Merger Offer
-
CAE (NYSE) INVESTOR ALERT: CAE, Inc. Investigated for Securities Fraud from Impairment Charges, Contact BFA Law if You Suffered Losses
-
BIIB (NASDAQ) FRAUD ALERT: Biogen Inc. Investors who Lost Money are Encouraged to Contact BFA Law about Upcoming Legal Deadline
-
NIO Inc. Provides May 2024 Delivery Update
-
XPENG Announces Vehicle Delivery Results for May 2024
-
Subsea7 awarded four PLSV contracts in Brazil
-
Swiss Properties Invest has finalised the acquisition of an attractive commercial property in Koblenz in the Canton of Aargau
-
Clariane: Information on the Availability of an Amendment to the 2023 Universal Registration Document
-
ALL-TIME BEST MONTHLY SALES FOR THE KIA EV9 AND SPORTAGE SUVs LEAD KIA AMERICA TO SECOND BEST SALES MONTH IN COMPANY HISTORY IN MAY
-
'A Fu, the hutong gentleman'
-
HTX Ventures Invests in Babylon to Advance Trustless Bitcoin Staking
-
Pink Curing Salt: SPQR Seasonings Becomes Best-Selling #1 Brand On Amazon.com
-
VTRConnect Launches Real Estate Mega App
-
Flash News: OKX Lists WLD/USDC Spot Trading Pair
-
AnalytixInsight Reports 2023 Financial Results and Provides MCTO Status Update
-
Unigold Announces Extension of Non-Brokered Private Placement of up to $2,000,000
-
The Chemours Company Temporarily Pauses Titanium Dioxide Production at Altamira, Mexico Site Amid Severe Regional Drought
-
Skymizer Launches Groundbreaking LLM Accelerator IP for on-device LLM Inferencing, EdgeThought, the game-changer in on-device GenAI era.
-
Li Auto Inc. May 2024 Delivery Update
-
Cielo Announces Final Closing of Private Placement of Convertible Debenture Units